# HCT With PTCy in Higher-risk MDS

> **NCT06098313** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Asan Medical Center** · enrollment: 113 (estimated)

## Conditions studied

- Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)

## Interventions

- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06098313
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 113 (ESTIMATED)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06098313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06098313, "HCT With PTCy in Higher-risk MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06098313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*